Plasma β-thromboglobulin and Platelet Factor 4 Levels in Cardiac Valve Prosthesis
Thromboembolic complications occur frequently in patients who have undergone cardiac valve replacement and platelets are known to be actively involved in the pathogenesis of such thrombi, A method of in-vivo assessment of platelet function would be useful in the management of such patients. βTC and PF4 Levels, the indicators of platelet release reaction in-vivo were measured in 100 patients who had cardiac valve replacement at least six months previously) Group A-54 patients had porcine heterograft, Group B-32 patients had disc valves and Group C-14 patients had double valve replacement. Findings of these patients were compared with 50 controls. In the control group, the mean βTG was 27.6ng/ml, and PF4 9.0 ng/ml. In each of the three groups of operated patients, both mean βTC and PF 4 levels were significantly raised (p < 0.05). Group A 61.5 ng/ml and 26.5 ng/ml, Grout B 57.0 ng/ml and 19.6 ng/ml and Group C 63.0 ng/ml and 36.6 ng/ml respectively. Of the 100 cases studied, 57 involved mitral, 29 aortic and 14 multiple valve replacement. No significant differences were observed in βTC or PF4 plasma levels with the different type of valve involvement. The clinical implications of these results will be discussed.